Order results by:
| Issue | Title | |
| Vol 20, No 4 (2024) | Should a physician use the Beers criteria when prescribing direct oral anticoagulants to elderly patients? | Abstract similar documents |
| N. M. Vorobyeva, I. P. Malaya, V. D. Zakiev, O. N. Tkacheva | ||
| "... . The available evidence base for the use of rivaroxaban in elderly patients with AF and VTE and critical comments ..." | ||
| Vol 12, No 3 (2016) | THE ADVANCED TACTICS OF THE MANAGEMENT OF PATIENTS WITH VENOUS THROMBOEMBOLISM: THE ROLE OF RIVAROXABAN AT VARIOUS STAGES OF TREATMENT | Abstract PDF (Eng) similar documents |
| S. R. Gilyarevskiy | ||
| "... the validity of monotherapy tactics with rivaroxaban in patients with VTE. The results of this study ..." | ||
| Vol 14, No 5 (2018) | Bayer registered a new indication for rivaroxaban for use in patients with coronary heart disease or peripheral artery disease in the European Union and USA | Abstract similar documents |
| Bayer Company Press Release | ||
| "... антикоагулянта ривароксабана в дозе 2,5 мг 2 р/д в сочетании с 75-100 мг ацетилсалициловой кислоты один раз в ..." | ||
| Vol 16, No 2 (2020) | The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment | Abstract similar documents |
| К. V. Lobastov, I. V. Schastlivtsev | ||
| "... patients have been published: SELECT-D (rivaroxaban), HOKUSAI-VTE Cancer (edoxaban), ADAM VTE (apixaban ..." | ||
| Vol 12, No 5 (2016) | The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin | Abstract similar documents |
| I. Yu. Koroleva, I. V. Kolesnichenko, V. P. Nosov, M. V. Zlobin, D. I. Abelevich | ||
| "... Aim. To study the effect of rivaroxaban compared with warfarin on the incidence of cardioembolic ..." | ||
| Vol 10, No 3 (2014) | PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD | Abstract similar documents |
| L. Y. Koroleva, I. V. Kolesnichenko, V. P. Nosov, I. I. Gritsenko, E. S. Timoschenko | ||
| "... attractive, is rivaroxaban. ..." | ||
| Vol 11, No 6 (2015) | PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD | Abstract similar documents |
| L. Y. Koroleva, I. V. Kolesnichenko, V. P. Nosov, I. I. Gritsenko, E. S. Timoschenko | ||
| "... attractive, is rivaroxaban. ..." | ||
| Vol 8, No 3 (2012) | RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| M. Yu. Gilyarov | ||
| "... . The alternative antithrombotic agents, including rivaroxaban presented along with the traditional drugs (acetyl ..." | ||
| Vol 8, No 4 (2012) | THE RISK OF BLEEDINGS IN PATIENTS WITH ATRIAL FIBRILLATION DURING ANTICOAGULANT THERAPY | Abstract similar documents |
| M. Yu. Gilyarov | ||
| "... . Along with traditional drugs (acetylsalicylic acid, warfarin) rivaroxaban is specially considered ..." | ||
| Vol 15, No 5 (2019) | Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| "... . Direct oral anticoagulants, particularly rivaroxaban, are widely used for deep vein thrombosis/pulmonary ..." | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova | ||
| "... for two RCTs with rivaroxaban - EINSTEIN-DVT and EINSTEIN-PE) contained data on the participation of frail ..." | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| Sergey N. Bel'diev, Irina V. Medvedeva, Dmitry Yu. Platonov, Galina Yu. Trufanova | ||
| "... rivaroxaban among other non-vitamin K antagonist oral anticoagulants (NOAC): 1) none of the randomized ..." | ||
| Vol 17, No 6 (2021) | Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021 | Abstract similar documents |
| I. S. Yavelov | ||
| "... . The first prospective randomized controlled trial MICHELLE with direct oral anticoagulant rivaroxaban ..." | ||
| Vol 17, No 2 (2021) | The Role of Rivaroxaban in a Comprehensive Protection Strategy for Patients with Atrial Fibrillation | Abstract similar documents |
| I. A. Zolotovskaya, V. D. Sabanova, I. L. Davydkin | ||
| "... of this strategy is the control of comorbidities and risk factors for cardiovascular diseases. To date, rivaroxaban ..." | ||
| Vol 18, No 5 (2022) | Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova | ||
| "... thrombin blockers (dabigatran) or factor IIa blockers (apixaban, rivaroxaban, edoxaban). According ..." | ||
| Vol 12, No 4 (2016) | Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation | Abstract similar documents |
| S. G. Kanorskii | ||
| "... In XANTUS study the safety and efficacy of factor Xa inhibitor rivaroxaban were evaluated ..." | ||
| Vol 13, No 1 (2017) | CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova | ||
| "... Aim. To compare cost-effectiveness of the use of direct factor Xa inhibitors rivaroxaban ..." | ||
| Vol 13, No 5 (2017) | DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov | ||
| "... The opinion is expressed in some domestic publications that rivaroxaban has the most ..." | ||
| Vol 16, No 2 (2020) | The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| Vol 14, No 4 (2018) | Possibilities of Using Rivaroxaban in Elderly Patients with Atrial Fibrillation: Data from Randomized Studies and Real Clinical Practice | Abstract similar documents |
| N. M. Vorobyeva, O. N. kacheva | ||
| "... The possibility of rivaroxaban using in elderly patients with non-valvular atrial fibrillation ..." | ||
| Vol 15, No 4 (2019) | Elderly Patients with Atrial Fibrillation: Focus on Comorbidity and Safety of Anticoagulant Therapy | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova | ||
| "... results demonstrate a favorable efficiency and safety profile of rivaroxaban in comparison with warfarin ..." | ||
| Vol 13, No 5 (2017) | Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells | Abstract similar documents |
| Sergey Nikolaevich Bel'diev, Irina Vladimirovna Medvedeva, Dmitry Jur'evich Platonov | ||
| "... The opinion is expressed in some domestic publications that rivaroxaban has the most favorable ..." | ||
| Vol 12, No 1 (2016) | Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients with atrial fibrillation: terra incognita | Abstract similar documents |
| S. N. Bel'diev | ||
| "... Currently there are no generally accepted guidelines for the use of rivaroxaban together ..." | ||
| Vol 19, No 5 (2023) | Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease | Abstract similar documents |
| N. A. Shatalova, D. A. Sychev, K. B. Mirzaev, A. I. Kochetkov, E. Yu. Ebzeeva, V. B. Dashabylova, P. O. Bochkov, S. N. Tuchkova, S. V. Glagolev | ||
| "... equilibrium concentrations (Cmin,ss) of rivaroxaban in patients with non-valvular atrial fibrillation (AF ..." | ||
| Vol 14, No 5 (2018) | Anticoagulant Therapy in Difficult Patients with Atrial Fibrillation: When the Risks of Embolism and Bleeding Are Comparable | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova, M. A. Gabitova, L. N. Uddin | ||
| "... ) on rivaroxaban therapy are presented. Good efficacy and safety of full and reduced doses of rivaroxaban were ..." | ||
| Vol 18, No 3 (2022) | Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art | Abstract similar documents |
| S. R. Gilyarevsky | ||
| "... interactions of apixaban, rivaroxaban and dabigatran with the drugs most frequently used in patients ..." | ||
| Vol 18, No 6 (2022) | Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis | Abstract similar documents |
| L. V. Fedina, I. N. Sychev, T. D. Rastvorova, E. V. Strigunkova, A. A. Kachanova, Z. A. Sozaeva, P. O. Bochkov, A. V. Vardanyan, K. B. Mirzayev, D. A. Sychev | ||
| "... patients (50 patients received apixaban and 42 – rivaroxaban) with non-valvular atrial fibrillation ..." | ||
| Vol 19, No 1 (2023) | Value of Safety of Anticoagulant Therapy in Elderly Patient with Atrial Fibrillation and High Risk of Bleeding | Abstract similar documents |
| N. M. Vorobyeva, O. N. Tkacheva | ||
| "... safety of rivaroxaban in patients over 80 years of age, with a high risk of bleeding ..." | ||
| Vol 12, No 2 (2016) | THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE | Abstract similar documents |
| S. V. Moiseev | ||
| "... New oral anticoagulants that inhibit factor Xa (rivaroxaban, apixaban, edoksaban) or thrombin ..." | ||
| Vol 12, No 4 (2016) | Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true | Abstract similar documents |
| Yu. A. Bunin, S. V. Miklishanskaya | ||
| Vol 13, No 1 (2017) | DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT | Abstract similar documents |
| D. А. Napalkov, A. A. Sokolova, V. V. Fomin | ||
| "... was previously demonstrated in ARISTOTLE trial. On the contrary, rivaroxaban was associated with the most ..." | ||
| Vol 13, No 3 (2017) | PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION | Abstract similar documents |
| A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko | ||
| "... of genotype on rivaroxaban pharmacokinetics in the study involving the carriers of ABCB1 gene rs2032582 and rs ..." | ||
| Vol 7, No 5 (2011) | ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES | Abstract similar documents |
| Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy | ||
| Vol 9, No 3 (2013) | ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT | Abstract similar documents |
| E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts | ||
| Vol 11, No 3 (2015) | ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... and rivaroxaban). Aim. To assess the influence of apixaban use on the budget as an alternative to warfarin ..." | ||
| Vol 9, No 4 (2013) | COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS | Abstract similar documents |
| V. A. Sulimov, D. A. Napalkov, A. A. Sokolova | ||
| Vol 10, No 4 (2014) | NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova | ||
| "... dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile ..." | ||
| Vol 16, No 1 (2020) | Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice | Abstract similar documents |
| A. A. Zarudsky, A. A. Gavrilova, Т. S. Filinichenko | ||
| Vol 16, No 2 (2020) | Specificities of Approaches to Anticoagulant Therapy in Comorbid Patients with Atrial Fibrillation, Diabetes Mellitus and Impaired Kidney Function | Abstract similar documents |
| N. V. Drobotya, E. Sh. Guseynova, A. A. Pirozhenko | ||
| "... . Rivaroxaban may meet these requirements; its use has significant advantage in high adherence to therapy. ..." | ||
| Vol 16, No 3 (2020) | Coronary Artery Disease with a High Risk of Complications: How to Identify Such Patients and Choose Management Tactics? | Abstract similar documents |
| S. G. Kanorskii | ||
| "... of rivaroxaban and aspirin in high-risk groups, the rate of adverse events, including cardiovascular death ..." | ||
| Vol 16, No 4 (2020) | Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events? | Abstract similar documents |
| O. L. Barbarash, V. V. Kashtalap, I. A. Shibanova | ||
| "... and atherosclerosis of the peripheral arteries using a combination of the anticoagulant – rivaroxaban ..." | ||
| Vol 16, No 5 (2020) | New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants | Abstract PDF (Eng) similar documents |
| K. B. Mirzaev, D. V. Ivashchenko, I. V. Volodin, E. A. Grishina, K. A. Akmalova, A. A. Kachanova, A. I. Skripka, R. M. Minnigulov, T. E. Morozova, O. A. Baturina, A. N. Levanov, T. V. Shelekhova, A. I. Kalinkin, D. A. Napalkov, A. A. Sokolova, D. A. Andreev, I. N. Sychev, P. O. Bochkov, D. A. Sychev | ||
| "... Aim. To search for new pharmacogenetic biomarkers of bleeding risk in patients taking rivaroxaban ..." | ||
| Vol 17, No 1 (2021) | Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction | Abstract similar documents |
| Z. D. Kobalava, A. A. Shavarov, M. V. Vatsik-Gorodetskaya | ||
| Vol 17, No 2 (2021) | Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions | Abstract similar documents |
| V. A. Ionin, O. I. Bliznuk, E. I. Baranova, E. V. Shlyakhto | ||
| "... : rivaroxaban - 180/384 (46,9%) patients, dabigatran etexilate - 110/384 (28,6%) patients, apixaban - 94/384 (24 ..." | ||
| Vol 17, No 2 (2021) | Analysis of Anticoagulant Therapy in the Elderly Patients, in Clinical Practice of Family Medicine Centers in the Kyrgyz Republic | Abstract similar documents |
| S. M. Mamatov, B. Kanat kyzy, A. O. Musakeev, N. K. Kinderbaeva, T. J. Tagaev | ||
| "... warfarin, while only 11.8% had adequate INR control after one year of follow-up. Rivaroxaban was prescribed ..." | ||
| Vol 14, No 6 (2018) | The Results of Rivaroxaban Studies COMMANDER HF and MARINER Were Published. Bayer Company Press Release . | Abstract PDF (Eng) similar documents |
| artilce Editorial | ||
| Vol 17, No 3 (2021) | An Integrated Approach to the Management of a Multimorbid Patient with Atrial Fibrillation from the Standpoint of Modern Guidelines: Rivaroxaban is in Focus | Abstract similar documents |
| V. N. Larina, O. Sh. Oynotkinova, A. P. Majorova, G. A. Egiazarian, T. Yu. Demidova | ||
| "... of the concept of comprehensive patient protection. Rivaroxaban is considered by the authors of the article ..." | ||
| Vol 13, No 2 (2017) | RIVAROXABAN HAS DEMONSTRATED AN ADVANTAGE OVER ACETYLSALICYLIC ACID IN PREVENTING THE RECURRENCE OF VENOUS THROMBOEMBOLIC EVENTS IN THE EINSTEIN CHOICE STUDY | Abstract similar documents |
| . Editorial | ||
| "... эффективность и безопасность ривароксабана в дозах 20 мг 1 р/д*, 10 мг 1 р/д и ацетилсалициловой кислоты в дозе ..." | ||
| Vol 16, No 1 (2020) | Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients | Abstract similar documents |
| A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin | ||
| "... of antiplatelet therapy. The combination of rivaroxaban in a dose of 2.5 mg and standard double antiplatelet ..." | ||
| Vol 10, No 2 (2014) | RIVAROXABAN IN PATIENTS STABILIZED AFTER A ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION. RESULTS FROM THE ATLAS ACS-2–TIMI-51 TRIAL | Abstract similar documents |
| J. L. Mega, E. Braunwald, S. A. Murphy, A. N. Plotnikov, P. Burton, R. G. Kiss, A. Parkhomenko, M. Tendera, P. Widimsky, C. M. Gibson | ||
| "... Цель. Представлен анализ лечения ривароксабаном в заранее определенной подгруппе больных инфарктом ..." | ||
| Vol 11, No 5 (2015) | New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation | Abstract similar documents |
| article Editorial | ||
| "... rivaroxaban in patients with non-valvular atrial fibrillation ..." | ||
| Vol 13, No 5 (2017) | RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE OR PERIPHERAL ARTERIAL DISEASE | Abstract similar documents |
| статья Редакционная | ||
| Vol 17, No 4 (2021) | Effect of Direct Oral Anticoagulants for Ulcer Epithelization and Laser Doppler Flowmetry Parameters In Patients with Diabetic Foot Syndrome and Atrial Fibrillation | Abstract similar documents |
| V. I. Petrov, N. V. Rogova, T. N. Кuzmina, A. S. Lishuta | ||
| "... for DFS and rivaroxaban (group 1; n=24) or combination therapy for DFS and dabigatran (group 2; n=22 ..." | ||
| Vol 13, No 5 (2017) | ADHERENCE TO THE USE OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION – THE WAY TO SOLVE THE PROBLEM OF EFFICACY AND SAFETY OF TREATMENT | Abstract similar documents |
| S. G. Kanorskii | ||
| "... . Rivaroxaban can be given in fixed doses without routine coagulation control, and phase III studies and actual ..." | ||
| Vol 13, No 6 (2017) | PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS | Abstract similar documents |
| A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin | ||
| "... – rivaroxaban and apixaban) were included into the cohort study in parallel groups. In addition to evaluate ..." | ||
| Vol 11, No 1 (2015) | PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... , rivaroxaban and dabigatran. Along with clinical efficacy and safety profile one of the main characteristics ..." | ||
| Vol 15, No 6 (2019) | Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation | Abstract similar documents |
| M. A. Gabitova, P. M. Krupenin, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
| "... of age with confirmed AF, receiving dabigatran in a reduced dosage, apixaban or rivaroxaban in full ..." | ||
| Vol 15, No 6 (2019) | New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease | Abstract similar documents |
| N. B. Perepech | ||
| "... , which obtained confirmation of the positive effect of combined therapy with rivaroxaban ..." | ||
| Vol 16, No 1 (2020) | The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation | Abstract similar documents |
| A. N. Turov, S. V. Panfilov, О. V. Tschiglinzeva | ||
| "... , rivaroxaban – in 41.3% (n=178), apixaban – in 20.2% (n=87) of patients. Results. The incidence of new cases ..." | ||
| Vol 16, No 2 (2020) | Off-Label Medicines Use: Complex Problem of Modern Clinical Practice | Abstract similar documents |
| S. R. Gilyarevskiy | ||
| Vol 14, No 4 (2018) | Hepatotoxicity of New Oral Anticoagulants | Abstract similar documents |
| A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin | ||
| Vol 16, No 6 (2020) | An Elderly Comorbid Patient with Atrial Fibrillation: What is Important to Know and What Should be Considered When Prescribing Anticoagulants? | Abstract similar documents |
| T. V. Pavlova | ||
| "... the direct oral anticoagulant rivaroxaban showed a tendency to reduce the risk of thromboembolism by 20 ..." | ||
| Vol 15, No 3 (2019) | Treatment of Patients with Stable Manifestations of Atherosclerosis: New Opportunities | Abstract similar documents |
| article Editorial | ||
| "... of both coagulation and platelet). Experts noted that combination of rivaroxaban 2.5 mg BID ..." | ||
| Vol 19, No 3 (2023) | Current insights into the possible role of laboratory monitoring of effectiveness and safety of direct oral anticoagulants | Abstract similar documents |
| S. R. Gilyarevsky, N. K. Vereina, M. V. Golshmid | ||
| Vol 12, No 5 (2016) | Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease | Abstract similar documents |
| I. S. Daabul, A. A. Sokolova, D. A. Napalkov | ||
| Vol 15, No 5 (2019) | Anticoagulant Therapy as a Tool for the Prevention of Cognitive Impairment Associated with Atrial Fibrillation | Abstract similar documents |
| O. D. Ostroumova, A. I. Kochetkov, S. P. Korchagina, T. M. Ostroumova, M. S. Chernyaeva, A. A. Kirichenko | ||
| "... strategy for preventing stroke associated with AF. Among the DOAC class, rivaroxaban is worth noticing ..." | ||
| Vol 18, No 1 (2022) | The Impact of Combination Therapy with Rivaroxaban and Acetylsalicylic Acid in Patients with Coronary Heart Disease on the Achievement of the Target for Reducing Mortality from Cardiovascular Diseases of the Federal Project "Fight against Cardiovascular Diseases" | Abstract similar documents |
| M. V. Zhuravleva, A. V. Panov, A. R. Kuksenok | ||
| "... Aim. To assess the outcomes of combination therapy with rivaroxaban and acetylsalicylic acid (ASA ..." | ||
| Vol 18, No 6 (2022) | Left Ventricular Thrombosis: Current Perspective and Use of Direct Oral Anticoagulants | Abstract similar documents |
| A. D. Aga, A. A. Sokolova, D. A. Napalkov | ||
| Vol 11, No 3 (2015) | PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT | Abstract similar documents |
| A. V. Rudakova | ||
| "... Venous thromboembolic (VTE) events are a major concern in large joints replacement leading ..." | ||
| Vol 4, No 3 (2008) | THE RUSSIAN DATA OF INTERNATIONAL ENDORSE REGISTER (EPIDEMIOLOGIC INTERNATIONAL DAY FOR THE EVALUATION OF PATIENTS AT RISK OF VENOUS THROMBOSIS IN ACUTE HOSPITAL CARE SETTING) | Abstract similar documents |
| V. A. Sulimov, S. M. Belentsov, N. I. Golovina, N. P. Dubrovnaja, K. P. Zhidkov, K. V. Yeliseyeva, P. O. Kazanchan, A. V. Redkin, G. V. Rodoman, I. L. Fridman, V. N. Shershnev | ||
| "... Aim. To estimate a risk factor frequency of venous thromboembolism (VTE) in patients urgently ..." | ||
| Vol 12, No 6 (2016) | NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY | Abstract similar documents |
| article editorial | ||
| Vol 10, No 6 (2014) | THE PROBLEM OF THE USE OF NEW ORAL ANTICOAGULANTS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY | Abstract similar documents |
| A. A. Rumyantsev, I. A. Pokataev, T. V. Kozlov, N. A. Rumyantsev | ||
| "... Despite large number of known risk factors of venous thromboembolism (VTE) in cancer patients ..." | ||
| Vol 17, No 3 (2021) | Treatment and Secondary Prevention of Venous Thromboembolism in Real Clinical Practice Based on Health Care Professional Survey | Abstract similar documents |
| K. V. Lobastov, A. R. Navasardyan, I. V. Schastlivtsev | ||
| "... Aim. To assess the duration of the anticoagulant treatment of venous thromboembolism (VTE ..." | ||
| Vol 11, No 6 (2015) | Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events | Abstract similar documents |
| O. V. Shatalova | ||
| "... with venous thromboembolism (VTE). Material and methods. Economic evaluation was performed from a position ..." | ||
| Vol 11, No 5 (2015) | Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism | Abstract similar documents |
| A. V. Rudakova | ||
| "... of venous thromboembolism (VTE) compared with low molecular weight heparin (LMWH)/warfarin and other new ..." | ||
| Vol 9, No 2 (2013) | ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES | Abstract similar documents |
| Z. M. Safiullina, S. V. Shalaev | ||
| "... inhibitors of coagulation factor Xa (rivaroxaban, apixaban), in the treatment of nonvalvular atrial ..." | ||
| Vol 19, No 3 (2023) | Recurrent bleeding during standard anticoagulant therapy in comorbid patients with atrial fibrillation: a clinical case report | Abstract similar documents |
| A. A. Kudriavtseva, E. V. Kolpachkova, Z. A. Gebekova, T. A. Sadulaeva, A. A. Sokolova, D. A. Napalkov | ||
| "... extremities and hemarthrosis of the knee joint while taking 20 mg of rivaroxaban in a 72-year-old patient ..." | ||
| Vol 18, No 3 (2022) | Risk of Venous Thromboembolic Complications in Patients with Atrial Fibrillation: a Systematic Review and Meta-analysis | Abstract PDF (Eng) similar documents |
| A. A. Sokolova, A. A. Kudriavtseva, N. V. Kostokova, M. P. Zaikina, Z. A. Gebekova, D. A. Napalkov, I. A. Zolotukhin | ||
| "... between AF and VTE. Material and methods. Atrial fibrillation (AF) and atrial flutter (AFL) contribute ..." | ||
| Vol 12, No 6 (2016) | Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis | Abstract PDF (Eng) similar documents |
| V. I. Petrov, O. V. Shatalova, V. S. Gorbatenko, O. N. Smuseva, A. S. Maslakov | ||
| "... of venous thromboembolism (VTE). Material and methods. This meta-analysis of randomized controlled trials ..." | ||
| Vol 12, No 1 (2016) | Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis | Abstract similar documents |
| V. I. Petrov, O. V. Shatalova, V. S. Gorbatenko, O. N. Smuseva, A. S. Maslakov | ||
| "... of venous thromboembolism (VTE). Material and methods. This meta-analysis of randomized controlled trials ..." | ||
| Vol 17, No 4 (2021) | Changes in anticoagulant prescription in a general hospital in 2008-2018 | Abstract similar documents |
| E. B. Kleymenova, V. A. Otdelenov, M. D. Nigmatkulova, S. A. Payushchik, A. A. Chernov, O. D. Konova, L. P. Yashina, A. M. Cherkashov, D. A. Sychev | ||
| "... oral anticoagulants (DOAC) prescription in clinical guidelines for venous thromboembolism (VTE) and AF ..." | ||
| Vol 18, No 1 (2022) | Polymorbidity and Polypragmasia in High and Very High Cardiovascular Risk Patients | Abstract similar documents |
| N. V. Izmozherova, A. A. Popov, A. A. Kuryndina, E. I. Gavrilova, M. A. Shambatov, V. M. Bakhtin | ||
| "... . Определена частота полипрагмазии с помощью критериев STOPP/START и критериев Бирса 2019 г., проведен анализ ..." | ||
| Vol 9, No 6 (2013) | THE ROLE OF P-GLYCOPROTEIN IN RATIONAL PHARMACOTHERAPY IN CARDIOLOGY | Abstract similar documents |
| A. V. Shulkin, E. N. Yakusheva, N. M. Popova | ||
| "... , prasugrel) and anticoagulants (dabigatran etexilate, rivaroxaban, edoxaban) is not feasible in routine ..." | ||
| Vol 21, No 1 (2025) | The Beers criteria role in predicting bleeding during the use of direct oral anticoagulants in patients with atrial fibrillation over 80 years of age | similar documents |
| M. S. Cherniaeva, M. A. Rozhkova, E. S. Ilyina, E. A. Moiseeva, E. A. Gorelov, L. A. Egorova, O. M. Maslennikova, N. V. Lomakin, D. A. Sychev | ||
| "... ) согласно критериям Бирса и оценить их роль в прогнозировании клинически значимого небольшого кровотечения ..." | ||
| Vol 14, No 6 (2018) | Anticoagulant Therapy in “Fragile” Elderly Patients: Current State of the Problem | Abstract PDF (Eng) similar documents |
| N. M. Vorobyeva, O. N. Tkacheva | ||
| "... showed that only therapy with rivaroxaban (out of three direct oral anticoagulants) compared ..." | ||
| Vol 16, No 4 (2020) | The Controversy Continues Again: which Direct Anticoagulant is More Effective and Safe when Administered to Patients with Atrial Fibrillation? | Abstract similar documents |
| S. Yu. Martsevich | ||
| "... . The authors analyzed a large database of patients with atrial fibrillation and concluded that rivaroxaban ..." | ||
| Vol 18, No 1 (2022) | Modern Anticoagulant Therapy for Atrial Fibrillation: Patient Adherence in Clinical Practice | Abstract similar documents |
| Yu. P. Skirdenko, N. A. Nikolaev, K. G. Pereverzeva, A. Yu. Timakova, A. S. Galus, S. S. Yakushin | ||
| "... , 99% of respondents received anticoagulant treatment. Rivaroxaban was the leader in prescribability ..." | ||
| Vol 20, No 2 (2024) | Characteristics of the Russian population of patients with coronary artery disease or peripheral artery disease in the XATOA registry | Abstract similar documents |
| V. S. Arakelyan, A. D. Erlikh, N. Sh. Amirov, E. Dubar, K. Vogtlaender, S. Debus | ||
| "... inhibition therapy with rivaroxaban 2,5 mg twice a day and low-dose acetylsalicylic acid (ASA) daily were ..." | ||
| Vol 17, No 6 (2021) | Renal Function Protection as an Important Component of a Comprehensive Approach to the Management of Patients with Atrial Fibrillation | Abstract similar documents |
| T. V. Pavlova | ||
| "... rivaroxaban has been most studied in a population of comorbid AF and CKD patients and has proven a high ..." | ||
| Vol 11, No 2 (2015) | ANTICOAGULANT THERAPY IN EVERYDAY CLINICAL PRACTICE: DATA OF THE RETROSPECTIVE CROSS-SECTIONAL STUDY | Abstract PDF (Eng) similar documents |
| V. A. Sulimov, D. A. Napalkov, A. A. Sokolova, A. V. Jilenko, O. S. Anikina | ||
| "... % of the patients received novel oral anticoagulants (dabigatran – 14%, rivaroxaban – 2%). Bleeding was fixed in 4 ..." | ||
| Vol 16, No 6 (2020) | The Oral Anticoagulants Administration in Elderly Patients with Geriatric Syndromes: What's New? | Abstract similar documents |
| N. M. Vorobyeva, O. N. Tkacheva | ||
| "... , rivaroxaban, apixaban, and edoxaban) over the vitamin K antagonist warfarin in elderly patients with geriatric ..." | ||
| Vol 17, No 5 (2021) | Gastrointestinal Bleeding: a Cardiologist's Point of View | Abstract similar documents |
| O. V. Averkov, L. N. Mishchenko | ||
| "... antagonists (warfarin) as well as direct oral anticoagulants (DOAC): dabigatran, rivaroxaban, apixaban ..." | ||
| Vol 12, No 1 (2016) | Взаимодействие ривароксабана с амиодароном, верапамилом и дилтиаземом у пациентов с фибрилляцией предсердий: terra incognita | Abstract similar documents |
| "... В настоящее время отсутствуют общепринятые рекомендации по применению ривароксабана совместно с ..." | ||
| Vol 14, No 2 (2018) | NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING | Abstract similar documents |
| Zh. D. Kobalava, S. V. Villevalde, A. A. Shavarov | ||
| "... given rivaroxaban appeared to have higher rate of hemorrhagic events. High adherence to apixaban ..." | ||
| Vol 12, No 5 (2016) | Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation | Abstract similar documents |
| N. A. Novikova, A. N. Volovchenko | ||
| "... showed the efficacy and safety of rivaroxaban and apixaban in preparation and performance of electrical ..." | ||
| Vol 14, No 2 (2018) | New Possibilities of Antithrombotic Therapy of Patients with Peripheral and Widespread Atherosclerotic Lesion | Abstract similar documents |
| A. L. Komarov, Е. S. Novikova, E. V. Guskova, Е. B. Yarovaya, A. N. Samko, E. Р. Panchenko | ||
| "... , that was demonstrated in a recently published study COMPASS. Treatment with rivaroxaban small doses in addition ..." | ||
| Vol 17, No 5 (2021) | Optimum Treatment Strategy in Chronic Coronary Syndromes: the New Trials vs the Current Guidelines | Abstract similar documents |
| L. L. Bershtein, E. V. Zbyshevskaya, V. E. Gumerova | ||
| "... of a second antithrombotic drug – rivaroxaban in a small dose (2.5 mg BID) – is recommended for patients ..." | ||
| Vol 17, No 4 (2021) | Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention | Abstract similar documents |
| A. V. Panov | ||
| "... of rivaroxaban, which create the possibility of its single administration, the evidence base for reducing ..." | ||
| Vol 13, No 5 (2017) | WARFARIN AND ITS IMPORTANCE IN THE ERA OF NEW ORAL ANTICOAGULANTS. ISSUES OF MONITORING THE EFFECTIVENESS AND SAFETY OF TREATMENT | Abstract similar documents |
| S. Yu. Martsevich, Y. V. Lukina | ||
| "... of new OAC (NOAC) also appeared. In Russia, dabigatran, rivaroxaban and apixaban have been registered ..." | ||
| Vol 14, No 6 (2018) | Antithrombotic Therapy in Patients with Atrial Fibrillation after Myocardial Infarction: Clinical Guidelines and Actual Practice | Abstract PDF (Eng) similar documents |
| K. G. Pereverzeva, S. S. Yakushin, A. E. Pripadcheva, N. P. Agaltsova | ||
| "... was prescribed in 11 (64.7%) cases and rivaroxaban – in 6 (35.3%). Conclusion. In real clinical practice ..." | ||
| 1 - 100 of 107 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
.jpg)
